bioRxiv Science⌕ Search

Biology subjects

Acker, C.

Publications and source records attributed to Acker, C..

2 recordsLinked to original sources

Tethered Bichromophoric Fluorophore Quencher Voltage Sensitive Dyes

Voltage sensitive dyes (VSDs) are used for in vitro drug screening and for in vivo imaging of patterns of electrical activity. However, wide application of this technology is limited by poor sensitivity. A promising approach uses a 2-component system consisting of charged membrane permeable quenchers together with fluorophores labeling one side of the membrane; this produces voltage-dependent fluorescence quenching. However, to achieve good sensitivity, the quencher compound must be used at high concentrations, which can perturb the membrane capacitance or have other pharmacological effects. By developing tethered bichromophoric fluorophore quencher (TBFQ) dyes, where the fluorophore and quencher are covalently connected by a long hydrophobic chain, the concentration required is minimized, and the sensitivity is maximized. A series of 13 TBFQ dyes based on the AminoNaphthylEthenylPyridinium (ANEP) fluorophore and the dipicrylamine anion (DPA) quencher have been synthesized and tested in an artificial lipid bilayer apparatus. The best one from the screening, TBFQ1, shows a 2.5 fold change in fluorescence per 100mV change in membrane potential, and the response kinetics is in 10-20 ms range. This sensitivity is an order of magnitude better than commonly used fluorescent voltage sensors. The design principles for TBFQ VSDs described here can be readily extended to other spectral regions and promise to greatly enhance our ability to monitor electrical activity in cells and tissues.

biophysics↗

A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides

Strategies aimed at reducing cerebral accumulation of the amyloid-{beta} (A{beta}) peptides have therapeutic potential in Alzheimers disease (AD). A{beta} immunization has proven to be effective at promoting A{beta} clearance in animal models but adverse effects have hampered its clinical evaluation. The first anti-A{beta} immunization clinical trial, which assessed a full-length A{beta}1-42 vaccine, increased the risk of encephalitis most likely because of autoimmune pro-inflammatory T helper 1 (Th1) response against all forms of A{beta}. Immunization against less abundant but potentially more pathologically relevant A{beta} products, such as N-terminally-truncated pyroglutamate-3 A{beta} (A{beta}pE3), could provide efficacy and improve tolerability in A{beta} immunotherapy. Here, we describe a selective vaccine against A{beta}pE3 using the diphtheria toxin mutant CRM197 as carrier protein for epitope presentation. CRM197 is currently used in licensed vaccines and has demonstrated excellent immunogenicity and safety in humans. In mice, our A{beta}pE3:CRM197 vaccine triggered the production of specific anti-A{beta}pE3 antibodies that did not cross-react with A{beta}1-42, non-cyclized A{beta}E3, or N-terminally-truncated pyroglutamate-11 A{beta} (A{beta}pE11). A{beta}pE3:CRM197 antiserum strongly labeled A{beta}pE3 in insoluble protein extracts and decorated cortical amyloid plaques in human AD brains. Anti-A{beta}pE3 antibodies were almost exclusively of the IgG1 isotype, suggesting an anti-inflammatory Th2 response bias to the A{beta}pE3:CRM197 vaccine. To the best of our knowledge, this study shows for the first time that CRM197 has potential as a safe and suitable vaccine carrier for active and selective immunization against specific protein sequence modifications or conformations, such as A{beta}pE3.

neuroscience↗